Benchling adds another megaround into the fold, looking even more unicorn-y as a possible IPO approaches

Touting its mission to revolutionize R&D by bringing drug development into the cloud, Benchling has earned its unicorn horn from investors hungry for something new. A new round of financing will now drive that eye-popping valuation even higher.

Just seven months after raising $200 million from investors in a Series...

Click to view original post